The following trials are open to patients with newly diagnosed and
recurrent glioblastoma:
Recurrent Glioma
Compassionate Use Trial of Temodol in Recurrent Malignant
Glioma.
Eligibility: Recurrent Malignant Glioma.
Protocol: Temodal, an oral agent, is taken five days out of each 4 week period.
Newly Diagnosed Anaplastic Oligodendroglioma and Oligoastrocytoma
Phase II study of High-Dose Carboplatin Prior to Radiation
Therapy
Eligibility: Newly diagnosed anaplastic astrocytoma, glioblastoma multiforme
Protocol: up to four cycles of Carboplatin are given prior to the administration of local field
radiation therapy. Follow-up chemotherapy is then given.
Newly Diagnosed Anaplastic Oligodendroglioma or
Oligoastrocytoma
Phase III Intergroup Randomized Comparison of Radiation
Alone vs Pre-Radiation Chemotherapy for Pure and Mixed Anaplastic Oligodendrogliomas (RTOG 9402)
Eligibility: Patients with previously untreated anaplastic oligodendroglioma or mixed oligodendroglioma-astrocytoma
18 years or older are eligible.
Protocol: This is a randomized study. Half of the patients will receive chemotherapy prior to radiation,
the other half will receive radiation as the initial therapy.
Recurrent Anaplastic Oligodendroglioma and Oligoastrocytoma
Phase I/II dose escalation study of Carboplatin and
Thalidomide in recurrent high grade glioma
Eligibility: Recurrent high grade glial neoplasm, no prior carboplatin or cisplatinum based chemotherapy.
Protocol: Carboplatin is administered monthly and Thalidomide is administered daily. Up to six
courses of therapy may be given.
Newly Diagnosed or Anaplastic Oligodendroglioma and Oligoastrocytoma
Phase II study of high-dose Carboplatin/Thiotepa with
autologous stem-cell support in newly diagnosed or recurrent high grade glioma
Eligibility: Newly diagnosed or recurrent high grade glial neoplasm, No prior Thiotepa, Carboplatin,
or Cisplatinum based chemotherapy.
Protocol: Following stem-cell harvest, high-dose Carboplatin and Thiotepa are administered followed
by stem cell re-infusion. Two cycles of therapy are given.
Recurrent Anaplastic Oligodendroglioma and Oligoastrocytoma
Phase II study of high-dose Cyclophosphamide/Etoposide
with gCSF support in recurrent high grade glioma
Eligibility: Recurrent high grade glial neoplasm, No prior Cyclophosphamide or Etoposide,
and failure of radiation therapy and carboplatin-based chemotherapy.
Protocol: high-dose Cyclophosphamide and Etoposide are followed by gCSF support. Treatment is repeated
as tolerated.
|
